Opinion|Videos|November 15, 2024
Addressing Payer Coverage Challenges
Key Takeaways
- Quadruplet regimens face payer coverage challenges, including prior authorization and high patient costs, impacting access to treatment.
- Providers address these challenges through proactive payer communication and presenting clinical evidence to support regimen efficacy.
Panelists discuss how they navigate challenges with payer coverage for quadruplet regimens in multiple myeloma treatment, including strategies they employ to address insurance denials or restrictions, such as providing clinical justification, leveraging recent trial data, and collaborating with financial assistance programs to ensure patients can access optimal therapy despite potential coverage difficulties.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As a provider, have you noticed any difficulties regarding payer coverage for quadruplet regimens? If so, how have you addressed these challenges?
Advertisement
Related to this article
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Gut microbiome disruption from antianaerobic antibiotics weakens CAR T-cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5